Literature DB >> 33618840

Emerging Therapeutic Applications for Fumarates.

Ayla Hoogendoorn1, Thomas D Avery2, Jiahe Li3, Christina Bursill4, Andrew Abell2, Peter M Grace5.   

Abstract

Fumarates are successfully used for the treatment of psoriasis and multiple sclerosis. Their antioxidative, immunomodulatory, and neuroprotective properties make fumarates attractive therapeutic candidates for other pathologies. The exact working mechanisms of fumarates are, however, not fully understood. Further elucidation of the mechanisms is required if these drugs are to be successfully repurposed for other diseases. Towards this, administration route, dosage, and treatment timing, frequency, and duration are important parameters to consider and optimize with clinical paradigms in mind. Here, we summarize the rapidly expanding literature on the pharmacokinetics and pharmacodynamics of fumarates, including a discussion on two recently FDA-approved fumarates VumerityTM and BafiertamTM. We review emerging applications of fumarates, focusing on neurological and cardiovascular diseases.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  atherosclerosis; fumarates; ischemia-reperfusion injury; neurodegenerative disease; neuropathic pain

Mesh:

Substances:

Year:  2021        PMID: 33618840      PMCID: PMC7954891          DOI: 10.1016/j.tips.2021.01.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  116 in total

Review 1.  Ischemia and reperfusion--from mechanism to translation.

Authors:  Holger K Eltzschig; Tobias Eckle
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.

Authors:  Xiurong Zhao; Guanghua Sun; Jie Zhang; Shun-Ming Ting; Nicole Gonzales; Jaroslaw Aronowski
Journal:  Stroke       Date:  2015-05-14       Impact factor: 7.914

3.  Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms.

Authors:  Melanie S Brennan; Hiral Patel; Norm Allaire; Alice Thai; Patrick Cullen; Sarah Ryan; Matvey Lukashev; Pradeep Bista; Ron Huang; Kenneth J Rhodes; Robert H Scannevin
Journal:  Antioxid Redox Signal       Date:  2016-04-28       Impact factor: 8.401

4.  Activation of Nrf2 by dimethyl fumarate improves vascular calcification.

Authors:  Chae-Myeong Ha; Sungmi Park; Young-Keun Choi; Ji-Yun Jeong; Chang Joo Oh; Kwi-Hyun Bae; Sun Joo Lee; Ji-Hyun Kim; Keun-Gyu Park; Do Youn Jun; In-Kyu Lee
Journal:  Vascul Pharmacol       Date:  2014-08-16       Impact factor: 5.773

5.  Fumarate decreases edema volume and improves functional outcome after experimental stroke.

Authors:  Bettina Hjelm Clausen; Louise Lundberg; Minna Yli-Karjanmaa; Nellie Anne Martin; Martina Svensson; Maria Zeiler Alfsen; Simon Bertram Flæng; Kristina Lyngsø; Antonio Boza-Serrano; Helle H Nielsen; Pernille B Hansen; Bente Finsen; Tomas Deierborg; Zsolt Illes; Kate Lykke Lambertsen
Journal:  Exp Neurol       Date:  2017-06-08       Impact factor: 5.330

Review 6.  The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis.

Authors:  Masayuki Yamamoto; Thomas W Kensler; Hozumi Motohashi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

7.  Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate.

Authors:  Arie R Gafson; Constantinos Savva; Tom Thorne; Mark David; Maria Gomez-Romero; Matthew R Lewis; Richard Nicholas; Amanda Heslegrave; Henrik Zetterberg; Paul M Matthews
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-04-22

8.  Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes.

Authors:  Karl E Carlström; Ewoud Ewing; Mathias Granqvist; Alexandra Gyllenberg; Shahin Aeinehband; Sara Lind Enoksson; Antonio Checa; Tejaswi V S Badam; Jesse Huang; David Gomez-Cabrero; Mika Gustafsson; Faiez Al Nimer; Craig E Wheelock; Ingrid Kockum; Tomas Olsson; Maja Jagodic; Fredrik Piehl
Journal:  Nat Commun       Date:  2019-07-12       Impact factor: 14.919

9.  No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter.

Authors:  Jordi Aubets; Josep-Maria Jansat; Miquel Salva; Vicky M Birks; Richard J Cole; Jenny Lewis; Annabell Pitcher; Michael Hall
Journal:  Pharmacol Res Perspect       Date:  2019-12-02

10.  Dimethyl fumarate alleviates the nitroglycerin (NTG)-induced migraine in mice.

Authors:  Giovanna Casili; Marika Lanza; Alessia Filippone; Michela Campolo; Irene Paterniti; Salvatore Cuzzocrea; Emanuela Esposito
Journal:  J Neuroinflammation       Date:  2020-02-17       Impact factor: 8.322

View more
  3 in total

Review 1.  Repurposing Dimethyl Fumarate for Cardiovascular Diseases: Pharmacological Effects, Molecular Mechanisms, and Therapeutic Promise.

Authors:  Shilu Deepa Thomas; Niraj Kumar Jha; Bassem Sadek; Shreesh Ojha
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-19

2.  Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes.

Authors:  William R Swindell; Krzysztof Bojanowski; Ratan K Chaudhuri
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-11

Review 3.  The Epidermis: Redox Governor of Health and Diseases.

Authors:  Yosuke Ishitsuka; Dennis R Roop
Journal:  Antioxidants (Basel)       Date:  2021-12-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.